Julyana Gomes Maia

Julyana Gomes Maia

Auto-generated profile, based on publicly available information

Julyana Gomes Maia

Laboratório de Neurofisiologia, Departamento de Ciências Fisiológicas, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAna Carolina Dutra Tavares
Ana Carolina Dutra Tavares
AMAlex C. Manhães
Alex C. Manhães
KSKeila A. Semeão
Keila A. Semeão
JMJulyana G. Maia
Julyana G. Maia
LCLuciana A. Couto
Luciana A. Couto
YAYael Abreu-Villaça
Yael Abreu-Villaça
The first symptoms of schizophrenia (SCHZ) are usually observed during adolescence, a developmental period during which first exposure to psychoactive drugs also occurs. These epidemiological findings point to adolescence as critical for nicotine addiction and SCHZ comorbidity, however it is not clear whether exposure to nicotine during this period has a detrimental impact on the development of SCHZ symptoms since there is a lack of studies that investigate the interactions between these conditions during this period of development. To elucidate the impact of a short course of nicotine exposure across the spectrum of SCHZ-like symptoms, we used a phencyclidine-induced adolescent mice model of SCHZ (2.5mg/Kg, s.c., daily, postnatal day (PN) 38-PN52; 10mg/Kg on PN53), combined with an established model of nicotine minipump infusions (24mg/Kg/day, PN37-44). Behavioral assessment began 4 days after the end of nicotine exposure (PN48) using the following tests: open field to assess the hyperlocomotion phenotype; novel object recognition, a declarative memory task; three-chamber sociability, to verify social interaction and prepulse inhibition, a measure of sensorimotor gating. Phencyclidine exposure evoked deficits in all analyzed behaviors. Nicotine history reduced the magnitude of phencyclidine-evoked hyperlocomotion and impeded the development of locomotor sensitization. It also mitigated the deficient sociability elicited by phencyclidine. In contrast, memory and sensorimotor gating deficits evoked by phencyclidine were neither improved nor worsened by nicotine history. In conclusion, our results show for the first time that nicotine history, restricted to a short period during adolescence, does not worsen SCHZ-like symptoms evoked by a phencyclidine-induced mice model.

23 May 2025 in Psychopharmacology
Verified
Journal Article
Closed access
ATAna Carolina Dutra Tavares
Ana Carolina Dutra Tavares
JMJulyana Gomes Maia
Julyana Gomes Maia
TSThainá Pereira Souza
Thainá Pereira Souza
CFCláudio Carneiro Filgueiras
Cláudio Carneiro Filgueiras
ARAnderson Ribeiro-Carvalho
Anderson Ribeiro-Carvalho
YAYael Abreu-Villaça
Yael Abreu-Villaça